
Cassava Sciences Investor Relations Material
Latest events

Status Update
Cassava Sciences

Q1 2025
8 May, 2025

Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cassava Sciences Inc
Access all reports
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s leading drug candidate, simufilam, is an oral small molecule in 3 clinical trials aimed at treating Alzheimer’s by targeting an altered form of a brain protein known as filamin A. Cassava Sciences is also developing SavaDx, an investigational diagnostic tool designed to detect Alzheimer's disease through a blood test. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SAVA
Country
🇺🇸 United States